Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis.

Hayes, Julia H.; Ollendorf, DA; Barry, Michael J.; Pearson, Steven D.; McMahon, Pamela M.

doi:10.1200/jco.2010.28.15_suppl.6012

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acceptance of IMRT has been based on data from retrospective studies that showed improvement in local control while maintaining target coverage and simultaneously minimizing the side effects by means of sparing organs at risk (OARs), particularly the rectum [1,3,4]. However, IMRT comes at a significantly higher monetary cost than 3D-CRT [5][6][7]. IMRT requires increased departmental resources through increased treatment planning times and increased physics quality assurance.…”

Section: Introductionmentioning

confidence: 99%